4-IODO-6-PHENYLPYRIMIDINE
4-IODO-6-PHENYLPYRIMIDINE 性质
沸点 | 380.2±30.0 °C(Predicted) |
---|---|
密度 | 1.728±0.06 g/cm3(Predicted) |
储存条件 | -20°C |
溶解度 | 在DMSO中的溶解度为10mg/mL(透明溶液,加热) |
形态 | 粉末 |
酸度系数(pKa) | -0.54±0.17(Predicted) |
颜色 | 白色至米色 |
InChIKey | ZTCJXHNJVLUUMR-UHFFFAOYSA-N |
4-IODO-6-PHENYLPYRIMIDINE 用途与合成方法
Target | Value |
MIF
() |
4-IPP is a specific suicide substrate for MIF that binds covalently and irreversibly to MIF to inhibit its biologic activity.
4-IPP inhibits RANKL-induced p65 phosphorylation and nuclear translocation by preventing the interaction of MIF with thioredoxin-interacting protein-p65 complexes.
4-IPP can inhibit receptor activator of NF-κB ligand (RANKL)-induced osteoclastogenesis and potentiate osteoblast-mediated mineralization and bone nodule formation.
4-IPP (0.5-200μM;24-72 hours) inhibits osteoclastogenesis in a dose-dependent manner.
4-IPP(5-20μM; 5 days) inhibits RANKL-induced osteoclast differentiation and bone resorption .
Cell Cytotoxicity Assay
Cell Line: | BMMs |
Concentration: | 0.5 μM, 1 μM, 2.5 μM, 5 μM, 10 μM, 25 μM, 50 μM, 100 μM, 200 μM |
Incubation Time: | 24 hours, 72 hours |
Result: | Inhibited osteoclastogenesis in a dose-dependent manner. |
Western Blot Analysis
Cell Line: | BMMs |
Concentration: | 5 μM,10 μM, 20 μM |
Incubation Time: | 1 day, 3 days, 5 days |
Result: | Inhibited RANKL-induced osteoclast differentiation and bone resorption. |
4-IPP (1 mg/kg, 5 mg/kg; every 2 days; for 8 weeks) ameliorates the bone loss associated with estrogen deficiency by reducing osteoclastic activities and enhancing osteoblastic bone formation.
Animal Model: | 8-weeks-old C57BL/6J male mice |
Dosage: | 1 mg/kg, 5 mg/kg |
Administration: | Intraperitoneal injection; every 2 days; for 8 weeks |
Result: | Alleviated OVX-induced osteoporosis. |
4-IODO-6-PHENYLPYRIMIDINE 价格(试剂级)
更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
---|---|---|---|---|---|
2024-11-08 | HY-110063 | 1 mg | 400 | ||
2024-11-08 | HY-110063 | 4-IODO-6-PHENYLPYRIMIDINE | 41270-96-6 | 5mg | 1150 |